{
    "eid": "2-s2.0-85051217524",
    "title": "Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents",
    "cover-date": "2018-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Watsamon Jantarabenjakul",
        "Suvaporn Anugulruengkitt",
        "Naruporn Kasipong",
        "Narukjaporn Thammajaruk",
        "Jiratchaya Sophonphan",
        "Torsak Bunupuradah",
        "Tim R. Cressey",
        "Angela Colbers",
        "David M. Burger",
        "Wanatpreeya Phongsamart",
        "Thanyawee Puthanakit",
        "Chitsanu Pancharoen"
    ],
    "citedby-count": 1,
    "ref-count": 27,
    "ref-list": [
        "British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013",
        "A systematic review of the psychiatric side-effects of efavirenz",
        "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)",
        "No evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data",
        "Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: An analysis of trial data",
        "Plasma efavirenz concentrations are associated with lipid and glucose concentrations",
        "Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load </= 100 000 copies/ml in the pooled ECHO and THRIVE Phase 3, randomized, double-blind trials",
        "Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA </=100,000 copies/ml: Week 96 pooled ECHO/THRIVE subanalysis",
        "Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/ tenofovir disoproxil fumarate vs. Efavirenz/emtricitabine/ tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults",
        "Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the Phase 3 double-blind randomized ECHO and THRIVE Trials",
        "Rilpivirine vs. Efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized Phase 3b study",
        "Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects",
        "Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens",
        "Rilpivirine as a treatment for HIV-infected antiretroviral-naive adolescents: Week 48 safety, efficacy, virology and pharmacokinetics",
        "Rilpivirine pharmacokinetics in HIV-1-infected adolescents: A substudy of PAINT (Phase II trial)",
        "Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals",
        "Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, Phase III trials ECHO and THRIVE",
        "Switch to rilpivirine/emtricitabine/tenofovir single-tablet regimen of human immunodeficiency virus-1 RNA-suppressed patients, Agence Nationale de Recherches sur le SIDA et les H\u00e9patites Virales CO3 Aquitaine Cohort, 2012\u20132014",
        "Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia",
        "Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: A cohort study",
        "Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: Implications for clinical management: The CREATE 1 study",
        "Impact of food and different meal types on the pharmacokinetics of rilpivirine"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60032499",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032499",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Liverpool",
            "@id": "60020661",
            "affilname": "University of Liverpool",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020661",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60011189",
            "affilname": "Faculty of Medicine Siriraj Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nijmegen",
            "@id": "60002573",
            "affilname": "Radboud University Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002573",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Department of Pharmacy & Radboud Institute for Health Sciences",
        "National Health Security Office",
        "RIHS",
        "Rad-boud University Medical Center",
        "amfAR, The Foundation for AIDS Research",
        "AIDS Life",
        "Chulalongkorn University",
        "Netherlands Space Office",
        "Republic of Korea National Red Cross",
        "Radboud Universitair Medisch Centrum",
        "Faculty of Tropical Medicine, Mahidol University"
    ]
}